zurig效果

Febuxostat () is a new anti-hyperuricemia drug developed by Teijin Company in Tokyo, Japan. It applied for marketing in Japan in early 2004. In April 2008, the European Union first approved the marketing of febuxostat tablets for the treatment of chronic hyperuricemia with uric acid deposition (including patients with gout stones and/or gouty arthritis, or patients with a history of this). The FDA approved the marketing of febuxostat tablets in February 2009. In the 2012 American College of Rheumatology Gout Guidelines, febuxostat was recommended as a Class A recommendation for drug treatment of patients with hyperuricemia and gout, which is also the first-line option. In June 2013, China's State Food and Drug Administration approved febuxostat for marketing in China.

When patients come into contact with a drug, they first need to know: what the drug treats and how effective it is. So, how effective is febuxostat (zurig) in treating gout?

The clinical data of 40 gout patients were collected in the clinical trial, and all case data were continuous and complete. According to the medication status of the patients, they were divided into febuxostat group and allopurinol group, with 20 cases in each group. Patients in the febuxostat group took febuxostat tablets orally, and patients in the allopurinol group took orally allopurinol. The serum uric acid levels, gout symptom improvement, post-treatment clinical effects and adverse reactions of the two groups of patients before and after treatment were observed.

Results Compared with the serum uric acid levels of the two groups of patients before treatment, the difference was not statistically significant; after treatment, the serum uric acid level of the patients in the febuxostat group [(372.55±90.80) μmol/L] was lower than that of the allopurinol group [(413.25±141.31) μmol/L], and the difference was statistically significant. The serum uric acid compliance rate (55.0%) and symptom improvement rate (95.0%) of patients in the febuxostat group were higher than those in the allopurinol group (35.0%, 85.0%), and the differences were statistically significant. The incidence of adverse reactions in the febuxostat group (20.0%) was lower than that in the allopurinol group (30.0%), and the difference was statistically significant.

From this we can know that febuxostat () has high selectivity and stronger activity. Its efficacy is better than that of allopurinol, the current gold standard treatment for gout, and it has fast efficacy and mild adverse reactions. As a new anti-uric acid drug, febuxostat has ended the history of allopurinol being the only drug in the world and created a new era of gout treatment.